Zobrazeno 1 - 10
of 159
pro vyhledávání: '"Chiao‐En Wu"'
Autor:
Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, Ruoh-Fang Yen, Chia-Chi Lin, Muh-Hwa Yang, Chueh-Chuan Yen, Wu-Chou Su, Chia-Jui Yen, Yi-Fang Chang, Ming-Fang Wu, Youngsen Yang, Chen-Yuan Lin, Wen-Chi Yang, Hui-Ching Wang, Cheng-Yuan Li, Yin-Yu Ho, Yao-Yu Chang, Chieh-Shan Wu, Hsiu-Cheng Hsu, Kuang-Hua Chen, Yenlin Huang, Chih-Jung Chen, Pei-Ju Chuang, Yung-Chi Lai, Yu-Yi Huang, Neng-Chuan Tseng, Yi-Ting Huang, Chia-Yu Chu, John Wen-Cheng Chang
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 1, Pp 7-15 (2024)
Melanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of the clinical
Externí odkaz:
https://doaj.org/article/04854f0faec04d159246a6f4a85d5aa9
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundEsophageal cancer (EC) is a major cause of cancer-related mortality in Taiwan and globally. Patients with EC are highly prone to malnutrition, which adversely affects their prognosis. While Chinese herbal medicine (CHM) is commonly used alo
Externí odkaz:
https://doaj.org/article/e263f9ed89d64b4a9cc48db9ad8e76ae
Autor:
Chiao-Ping Chen, Shu-Fu Lin, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Publikováno v:
Heliyon, Vol 10, Iss 7, Pp e29055- (2024)
Background: Anaplastic thyroid cancer (ATC), a rare and aggressive malignancy with a poor prognosis, has shown promise with the approved dabrafenib/trametinib combination for BRAFV600E mutation. Co-occurring PI3KCA mutations, identified as negative p
Externí odkaz:
https://doaj.org/article/ed076d5ed71b4007a7754c1b3c015f77
Autor:
Chen‐Te Wu, Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2548-2557 (2023)
Abstract Background This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer. Methods The clinical featu
Externí odkaz:
https://doaj.org/article/fc07701970254cbbb9979c7ef0d94271
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 15, p 8124 (2024)
Lung cancer is the leading cause of cancer mortality worldwide. Fortunately, the advent of precision medicine, which includes targeted therapy and immunotherapy, offers hope. However, identifying specific mutations is imperative before initiating pre
Externí odkaz:
https://doaj.org/article/28fc96e95bc7447dbc080151109d4bc0
Autor:
Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang, Li-Chung Chiu, Chiung-Hsin Chang, Ping-Chi Liu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Yu-Ching Lin, Cheng-Ta Yang, How-Wen Ko
Publikováno v:
Vaccines, Vol 12, Iss 5, p 474 (2024)
Real-world clinical experience of using anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (SCLC) patients has rarely been report
Externí odkaz:
https://doaj.org/article/fbd6cda30b6c4cde94dd95d9edb830f2
Autor:
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe clinical outcomes of sequential treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs are unclear. Thus
Externí odkaz:
https://doaj.org/article/db4839ec0a994a6298da90412b223b41
Autor:
Chiao-Ping Chen, Chun-Nan Yeh, Yi-Ru Pan, Wen-Kuan Huang, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115389- (2023)
Patients with advanced biliary tract cancer (BTC) have a poor prognosis, and novel treatments are needed. Gemcitabine, the standard of care for BTC, induces DNA damage; however, the ability of cancer cells to repair DNA dampens its effects. To improv
Externí odkaz:
https://doaj.org/article/28151b94a1054d259facfdc9571eff83
Autor:
John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 4, Pp 348-356 (2023)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse
Externí odkaz:
https://doaj.org/article/0d49cc0b61db45fda87814ded7764b7b
Autor:
John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 12-23 (2023)
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the efficacy of EGF
Externí odkaz:
https://doaj.org/article/34e2b99597da430da22ea8c1cd7a1a29